A word from our sponsors
Don’t miss the opportunity to learn about dengue with Takeda at WSPID
We are committed to advancing evidence-based measures to help prevent dengue and reduce its burden on children, families, and healthcare systems worldwide.1,2
Come to our symposium
Join us for a dynamic panel discussion with leading experts on the pressing challenges in dengue-endemic regions, highlighting prevention strategies, vaccine evidence, and the vital role of clinicians in driving meaningful change.
Time: 29 October, 17:30–18:30
Dengue Insights for Action: Evidence & Stories That Spark Change
Location: BH1 Hall
Explore our sessions below
Oral presentation: Evaluation of a Booster Dose of the Tetravalent Dengue Vaccine, TAK-003, in Healthy Children in Dengue-Endemic Regions (DEN-301).
E-poster discussion: Two Years of Post-marketing Experience with Takeda’s Live-attenuated Dengue Vaccine—A Safety Data Review.
29 October, 12:30–13:45
Location: Station 1
E-poster viewing: Innovative Design and Implementation Tools for a Post-Approval Dengue Vaccine Effectiveness Study Requiring Primary Data Collection (DEN-401).
See why dengue, the fastest-growing mosquito-borne viral disease worldwide, poses an urgent public health challenge in this short video.1,2
Dengue Mosquito Awareness
Takeda is a proud sponsor of WSPID.
Oral presentation: Evaluation of a Booster Dose of the Tetravalent Dengue Vaccine, TAK-003, in Healthy Children in Dengue-Endemic Regions (DEN-301).
E-poster discussion: Two Years of Post-marketing Experience with Takeda’s Live-attenuated Dengue Vaccine—A Safety Data Review.
29 October, 12:30–13:45
Location: Station 1
E-poster viewing: Innovative Design and Implementation Tools for a Post-Approval Dengue Vaccine Effectiveness Study Requiring Primary Data Collection (DEN-401).
The Takeda symposium is not included in main event CME/CPD credits. It has been organized and funded by Takeda, including compensation for external speakers acting as consultants. This program is not affiliated with WSPID. This session is open to healthcare professionals attending WSPID only. Discussions may include scientific data or perspectives that are subject to differences in regulatory approval across countries. Healthcare professionals should always rely on their own clinical judgement and refer to the approved prescribing information in their country. Distribution of material post-event is not permitted (Thai HCPs).
References: 1.World Health Organization. Comprehensive guidelines for prevention and control of dengue and dengue haemorrhagic fever. Revised and expanded edition. Accessed September 26, 2025. https://iris.who.int/handle/10665/204894 2. Areas with risk of dengue. Centers for Disease Control and Prevention. September 5, 2025. Accessed September 26, 2025. https://www.cdc.gov/dengue/areas-with-risk/
© Copyright 2025 Takeda Pharmaceuticals International AG.
Takeda and the Takeda Logo are registered trademarks of Takeda Pharmaceutical Company Limited. All rights reserved.
C-APROM/INT/QDE/0095 | October 2025
